Inhibitors of Akt activity

Details for Australian Patent Application No. 2005316826 (hide)

Owner Merck & Co., Inc.

Inventors Layton, Mark E.; Campbell, Brian T.; Siu, Tony; Cosford, Nicholas D. P.; Hu, Essa H.; Rodzinak, Kevin J.; Tehrani, Lida R.; Hoffman, Jacob M.; Liang, Jun; Li, Yiwei; Arruda, Jeannie M.; Stearns, Brian A.

Agent Spruson & Ferguson

Pub. Number AU-A-2005316826

PCT Pub. Number WO2006/065601

Priority 60/636,203 15.12.04 US

Filing date 9 December 2005

Wipo publication date 22 June 2006

International Classifications

A61K 31/4745 (2006.01)

C07D 471/02 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

28 June 2007 PCT application entered the National Phase

  PCT publication WO2006/065601 Priority application(s): WO2006/065601

6 March 2008 Amendment Made

  The nature of the amendment is: Amend the names of the co-inventors to add Bilodeau, Mark T and Manley, Peter J. 2006

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

5 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005316827-Safety system architecture for a hydrogen fueling station

2005316825-N-biaryl and N-arylheteroaryl piperazine derivatives as modulators of the 5HT2C receptor useful for the treatment of disorders related thereto